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Elimination of the NLRP3-ASC Inflammasome Protects
against Chronic Obesity-Induced Pancreatic Damage
Yun-Hee Youm,* Ayinuer Adijiang,* Bolormaa Vandanmagsar, David Burk,
Anthony Ravussin, and Vishwa Deep Dixit
Laboratory of Neuroendocrine-Immunology (Y.-H.Y., A.A., B.V., A.R., V.D.D.), Cell Biology and Imaging
Core (D.B.), and Pennington Biomedical Research Center (V.D.D.), Louisiana State University System,
Baton Rouge, Louisiana 70808
Clinical evidence that the blockade of IL-1 in type-2 diabetic patients improves glycemia is indic-
ative of an autoinflammatory mechanism that may trigger adiposity-driven pancreatic damage.
IL-1 is a key contributor to the obesity-induced inflammation and subsequent insulin resistance,
pancreatic -cell dysfunction, and the onset of type 2 diabetes. Our previous studies demonstrated
that the ceramides activate the Nod-like receptor family, pyrin domain containing 3 (Nlrp3) in-
flammasome to cause the generation of mature IL-1 and ablation of the Nlrp3 inflammasome in
diet-induced obesity improves insulin signaling. However, it remains unclear whether the post-
translational processing of active IL-1 in pancreas is regulated by the NLRP3 inflammasome or
whether the alternate mechanisms play a dominant role in chronic obesity-induced pancreatic
-cell exhaustion. Here we show that loss of ASC, a critical adaptor required for the assembly of the
NLRP3 and absent in melanoma 2 inflammasome substantially improves the insulin action. Sur-
prisingly, despite lower insulin resistance in the chronically obese NLRP3 and ASC knockout mice,
the insulin levels were substantially higher when the inflammasome pathway was eliminated. The
obesity-induced increase in maturation of pancreatic IL-1 and pancreatic islet fibrosis was de-
pendent on the NLRP3 inflammasome activation. Furthermore, elimination of NLRP3 inflam-
masome protected the pancreatic -cells from cell death caused by long-term high-fat feeding
during obesity with significant increase in the size of the islets of Langerhans. Collectively, this study
provides direct in vivo evidence that activation of the NLRP3 inflammasome in diet-induced obesity
is a critical trigger in causing pancreatic damage and is an important mechanism of progression
toward type 2 diabetes. (Endocrinology 152: 4039–4045, 2011)
Obesity is associated with self-directed tissue inflam-mation with the activation of immune cells in absence
of definitive pathogenic infection and as-of-yet unidenti-
fied autoantigens. Therefore, the obesity-induced inflam-
mation and the development of associated comorbidities
like type 2 diabetes (T2D) may qualify the established
criterion of autoinflammatory disease cluster described by
McGonagle and McDermott (1). It is established that in-
duction of inflammation is an important mechanism in the
development of insulin resistance and is a crucial event in
the pathogenesis of T2D (2–4). Among a broad array of
proinflammatory cytokines and chemokines, the IL-1
and TNF are considered to be key contributors to the
obesity-induced inflammation and subsequent insulin re-
sistance, pancreatic -cell dysfunction, and the onset of
T2D (3, 4). However, the early observations that TNF
induces insulin resistance in vitro and in mouse models
have not been supported by successful therapeutic out-
comes in several clinical trials in obese T2D patients (5–8).
Interestingly, recent randomized clinical trials demon-
strate that inhibition of IL-1 signaling leads to sustained
reduction in circulating C-reactive protein with an im-
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provement of T2D (9, 10). These data demonstrate that
alternate upstream proinflammatory mediators like IL-1,
which trigger the production of other secondary cytokines,
may be clinically relevant for management of obesity-in-
duced diseases including T2D. However, the mechanisms
that regulate the activation and posttranslational processing
of IL-1 during high-fat diet (HFD)-induced pancreatic dys-
function are incompletely understood.
Interestingly, the NOD-like receptors (NLR), innate
immune sensors, contribute to chronic inflammatory dis-
eases by sensing danger signals [danger-associated molec-
ular patterns (DAMP)], i.e. endogenous molecules that are
produced during organ dysfunction such as ceramides,
cholesterol crystals, urate, and -amyloid leading to ath-
erosclerosis, gout, and Alzheimer’s disease (11–14).
Among the NLR family, the activation of Nod-like recep-
tor family, pyrin domain containing 3 (NLRP3) (nucle-
otide-binding domain, leucine-rich-containing family, py-
rin domain containing-3) induces recruitment and
autocatalytic processing of cysteine protease caspase-1 in
a large cytosolic protein complex called inflammasome
(15). The activation of caspase-1 is required for the cleav-
age of stored pro forms of IL-1 into bioactive secreted
cytokines (16). The assembly of inflammasomes requires
the interaction of pyrin domain of ASC [for apoptosis-
associated speck-like protein containing carboxyl-termi-
nal caspase activation recruitment domain (CARD)] with
the pyrin domain of NLRP3 and formation of a functional
inflammasome complex through CARD-CARD interaction
of ASC with procaspase-1 zymogen (12, 15, 17). Recent
studies suggest that islet amyloid deposits in pancreas
can be sensed by the NLRP3 inflammasome to induce
IL-1 activation, and the mice overexpressing human
islet amyloid polypeptide (IAPP) produce higher
amounts of IL-1 (18). However, there is currently no
direct evidence that Nlrp3- or Asc-mediated inflam-
masome assembly impacts pancreatic function at various
stages of obesity. Our data establish that obesity-induced
pancreatic dysfunction and insulin levels are regulated by




The Asc/ and Nlrp3/ mice have been described previ-
ously (13). The mice were fed ad libitum HFD consisting of 60%
calories from fat (D12492i; Research Diets Inc., New Brunswick,
NJ) starting at 8 wk of age, and control mice were fed a standard
chow diet consisting of 4.5% fat (5002; LabDiet, Tallahassee,
FL). All experiments and animal use were conducted in compli-
ance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and were approved by the In-
stitutional Animal Care and Use Committee.
Insulin tolerance test (ITT) and glucose tolerance
test (GTT)
The ITT and GTT was conducted as described previously (13).
Insulin and leptin measurement
The serum level of hormones were measured using mouse
endocrine Milliplex bead assay as per manufacturer’s instruc-
tions. In addition, insulin levels reported in Fig. 3B were mea-
sured using mouse insulin ELISA kit (Millipore, Billerica, MA).
Western blot analysis
Adipose tissue and pancreas were snap frozen in liquid ni-
trogen to prepare protein lysates. The immunoblot analysis was
performed as described previously (13).
Histology and immunohistochemistry
The pancreas obtained from mice were either fixed in 4% for-
malin and paraffin embedded or flash frozen and subsequently em-
beddedinStephensScientific (Riverdale,NJ)frozensectionmedium
and cut into 5-m-thick cryostat sections. At least three cryosection
serial sections were used for each staining. The formalin-fixed, par-
affin-embedded sections were stained with hematoxylin and eo-
sin using autostainer (Dako, Carpinteria, CA), and fibrosis
was analyzed by trichrome staining. A total of 250 –286 islets
from four to six mice of each strain were counted, and the area
of each islet was determined by ImageJ software. Six nonserial
sections from each mouse were used to count the islets for size
measurement. The immunofluorescence confocal microscopy
was performed as described previously (13).
Results
Given theCARDdomainofASCproteinbinds to theCARD
domain of procaspase-1 for the assembly of NLRP3 and
absent in melanoma 2 (AIM2) inflammasomes and autoac-
tivation of caspase-1 (15), we determined the role of ASC in
caspase-1 processing and insulin action in diet-induced obesity.
We found that obesity induces the cleavage of the inactive p45
form of procaspase-1 into enzymatically active p20 het-
erodimer. Compared with wild-type (WT) diet-induced obese
(DIO) mice, the ablation of ASC prevented the HFD-induced
caspase-1 activation (Fig. 1A). Interestingly, the elimination of
ASC in DIO mice led to a significant improvement in insulin
action as measured by the ITT and GTT (Fig. 1, B and C).
To further understand the impact of the inflam-
masome-mediated proinflammatory state on the kinetics
of insulin levels, we aged the mice on chow and 60% HFD
until 1 yr and evaluated them at 3, 6, 9, and 12 months of
age. The HFD-fed mice had profound insulin resistance as
revealed by higher fasting insulin levels. Interestingly, in
1-yr-old DIO mice, the insulin levels tended to be lower
than 6-month-old DIO mice, suggesting potential defects
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in -cells to compensate for the increasingdegreeof insulin
resistance (Fig. 2A). We next aged the WT, Nlrp3/ and
Asc/ mice cohorts on chow and 60% HFD until 1 yr to
determine whether the inflammasome-dependent mecha-
nism plays a predominant role in regulation of insulin
levels, IL-1 activation, and -cell mass in obesity. In
chow-fed mice, ablation of NLRP3 and ASC did not affect
the fasting insulin levels (Fig. 2B). Consistent with our
previous data that the loss of NLRP3 (13) and current data
that ablation of ASC improves insulin sensitivity, we
found that compared with 3-month-old WT DIO control
animals, the Nlrp3/ and Asc/ mice on 60% HFD had
significantly lower insulin levels (Fig. 2B). In chow-fed
1-yr-old mice, we did not observe any significant differ-
ences between WT, Nlrp3/, and Asc/ mice (Fig. 2B).
Strikingly, compared with 12-month-old WT DIO mice,
age-matched Nlrp3/ and Asc/ DIO animals had sig-
nificantly higher fasting insulin levels (Fig. 2B) and lower
fasting glucose levels (Fig. 2C). Ablation of NLRP3 and
ASC had no impact on serum leptin levels in either chow-
or HFD-fed mice at 3 and 12 months of age (Fig. 3D).
Our previous studies identified that ceramides, which are
known to be elevated in obesity and T2D (19, 20), cause the
activation of IL-1 via the NLRP3 inflammasome-depen-
dent pathway (13). Therefore, we next investigated whether
the NLRP3 inflammasome pathway regulates the IL-1 pro-
cessing intotheactivep17formwithinthepancreasofchron-
ically obese mice. Compared with 9-month-old chow-fed
WT mice, the 9-month-old DIO mice displayed a substantial
increase in IL-1 activation, whereas the ablation of NLRP3
prevented an obesity-induced increase in the active p17
cleaved form of IL-1 (Fig. 3A). Consistent with our earlier
findings, examination of fasting insulin levels also revealed
significant increase in serum insulin concentration in a sep-
arate cohort of 9-month-old chronically DIO Nlrp3/ mice
but not in 6-month-old Nlrp3-deficient animals (Fig. 3B).
Interestingly, consistentwith the roleof IL-1-driven inflam-
mation in instigation of fibrosis, we found that pancreatic
islets of 9-month-old Nlrp3/ obese mice were protected
from extracellular matrix deposition and fibrosis.
Initial immunofluorescence confocal microscopy re-
vealed that compared with 1-yr-old chow-fed mice, the
insulin-stained pancreatic islets were substantially larger
in age-matched DIO mice (Fig. 3D). Of note, there was an
increase in IL-1 expression within the pancreatic islets of
DIO mice that was substantially lower upon ablation of
NLRP3 (Fig. 3D). Also, IL-1 was not colocalized within
the insulin-expressing -cells in the pancreatic islets, and
cytoplasmic IL-1 was expressed in F4/80-expressing
pancreatic macrophages (Fig. 3D). Further analysis re-
vealed that obesity-induced increase in -cell death was
reduced in the 1-yr-old Nlrp3/ obese mice (Fig. 4A). To
quantify whether the loss of Nlrp3 inflammasome-medi-
ated signaling in advanced obesity protects pancreatic is-
lets and to determine the size of the islets, we conducted
morphometric analysis of hematoxylin- and eosin-stained
pancreatic section from 1-yr-old WT and Nlrp3/ obese
mice. This analysis revealed that compared with WT DIO
mice, the elimination of NLRP3 led to a significant increase
in the size of pancreatic islets (Fig. 4, B and C). These results
establish that NLRP3 inflammasome activation is a key mech-
anism that causes HFD-induced pancreatic damage and may
participate in promoting the progression of an obesity-induced
insulin-resistant state toward the onset of T2D.
FIG. 1. Ablation of ASC lowers caspase-1 activation and improves
insulin action in DIO. A, Western blot analysis of caspase-1 in
epididymal fat (eFat) of C57/B6 mice. The activated p20 isoform of
caspase-1 increases during obesity and ablation of ASC, a critical
adaptor for NLRP3 inflammasome prevents autocatalytic activation of
caspase-1. B, The percent change in glucose levels after the ITT in WT
and ASC-deficient mice fed 60% HFD for 6 wk. The data are
presented as mean (SEM) with n  6. The drop in glucose levels after
insulin injection was significant at each time point (*, P  0.01). C, The
GTT in WT and ASC-deficient mice fed 60% HFD for 6 wk. The ASC
mice displayed significant reduction in glucose values after the ip
glucose injection (n  6).
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Discussion
It is established that IL-1 plays an important role in the
development of T2D (3, 4, 9, 10). IL-1 interacts with the
type 1 IL-1 receptor followed by recruitment of coreceptor
chain called the IL-1 receptor accessory protein to initiate
a proinflammatory cascade (21). Examination of several
organs including adipose tissue and lymphoid organs
show that the highest expression of type 1 IL-1 receptor is
observed in pancreatic islets (22). Several lines of evidence
indicate that the local IL-1 production in pancreatic islets
causes the cell death of -cells and compromises their abil-
ity to produce insulin (3, 4). Consistent with these data,
blocking IL-1 signaling in humans lowers the severity of
T2D (9, 10). However, the basic mechanism of posttrans-
lational processing through which IL-1 is cleaved and
activated and affects the pancreas dur-
ing various stages of obesity in not fully
understood. Notably, posttransla-
tional processing of IL-1 is complex
and can be regulated through several
inflammasomes, e.g. NLRP1 inflam-
masome, NLRC4 inflammasome,
NLRP3 inflammasome, and AIM2 in-
flammasome (17). Furthermore, pro-
IL-1 can be processed through
caspase-1- and inflammasome-indepen-
dent mechanisms. For example, several
neutrophil-andmacrophage-derivedser-
ine proteases such as proteinase-3, elas-
tase, and cathepsin G can also cleave the
pro-form of IL-1 (23, 24). Our data
demonstrate a specific role of NLRP3 in-
flammasome in the activation of IL-1
during chronic obesity-associated pan-
creatic damage.
The myeloid cell-expressed NLRP3 in-
flammasome has recently been implicated
insensingobesity-associateddangersignals
to cause IL-1- and IL-18-driven proin-
flammatory state that impairs insulin sen-
sitivity (13, 25). Given the expanded
adipose tissue with infiltrated macro-
phages is a major site of origin of in-
flammation in obesity (2, 13), we asked
whether the lack of ASC, which is re-
quired for the assembly of NLRP3
and AIM2 inflammasome, regulates
caspase-1 activation and insulin ac-
tion. These data revealed that within
6 wk of HFD feeding, the inflam-
masome is activated in the adipose tis-
sue, suggesting that caspase-1 activa-
tion is an early event that triggers the origin of
inflammation. Furthermore, the loss of ASC afforded
substantial protection from insulin resistance in early-
stage obesity, suggesting that in addition to NLRP3, the
AIM2 inflammasome may also participate in obesity-as-
sociated inflammation. We have previously shown that
elimination of NLRP3 can improve insulin action in mice
that are maintained on 60% HFD until 3, 6, and 9 months
of age (13). These previous studies showed that the
9-month-old Nlrp3/ obese mice had significantly lower
fasting glucose values with significant reduction in blood
glucose levels in response to glucose challenge (13). These
data prompted us to investigate the fasting insulin levels in
ASC- and NLRP3-null mice until 1 yr of HFD feeding. As
expected, the fasting insulin levels were significantly re-
FIG. 2. Ablation of Nlrp3 inflammasome improves pancreatic insulin production in chronic
obesity. A, The kinetics of fasting serum insulin levels in male C57/B6 mice fed the normal
chow diet and 60% HFD. The data are presented as mean (SEM) with n  5–8 per age group.
B, The kinetics of fasting serum insulin levels in WT, NLRP3/, and ASC/ mice fed normal
chow diet and 60% HFD up to 12 months. The data are presented as mean (SEM) with n 
5–8 (*, P  0.01). C and D, Fasting glucose levels (C) and kinetics (D) of fasting serum leptin
levels in in WT, NLRP3/, and ASC/ mice fed normal chow diet and 60% HFD up to 12
months. The data are presented as mean (SEM) with n  5–8.
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duced concomitant with improved insulin sensitivity in
early stages of obesity. In chronically obese 1 year old
mice, absence of Nlrp3 inflammasome lowers the severity
of insulin-resistance (IR) (13). Interestingly,despite relatively
lower IR, we observed 2- to 3-fold higher insulin levels in
chronically obese Nlrp3 knockout mice. These data suggest
that pancreatic Beta cells in obese Nlrp3 null mice are pro-
tectedfromHFDdiet-inducedinflammatorydamageandare
able to compensate by increasing insulin levels in face of
above normal glucose levels. Consistent with these data,
IL-1 has been shown to compromise -cell secretory func-
tion (26).However,additional studies in chronically obese
mice will be required to definitively address whether the
lack ofinflammasomeactivationimprovestheinsulinsecretion
capacity of pancreatic -cells. Furthermore, given that mi-
tochondrial reactive oxygen species are increased during
obesity and reactive oxygen species are implicated in Nlrp3
inflammasome assembly (27), it is possible that mitochon-
drial dysfunction could impact Nlrp3 inflammasome acti-
vation and lead to pancreatic damage in obesity.
The infiltration of activated immune cells in pancreas is
associated with the development of fibrosis as well as am-
FIG. 3. Elimination of Nlrp3 inflammasome protects pancreas from obesity-induced IL-1 damage and fibrosis. A, Immunoblotting for active (p17)
IL-1 in pancreas tissue lysates of WT and Nlrp3/ mice maintained on chow and HFD for 9 months. B, Fasting serum insulin levels in a different
cohort of WT and Nlrp3/ mice fed chow and HFD for 6 and 9 months. All data are presented as mean  SEM; n  6–10 mice. *, P  0.05. C,
The trichrome staining of pancreatic cryosections from 9-month-old WT and Nalp3/ mice fed 60% HFD. The deposition of collagen and fibrosis
can be identified by light blue regions within the pancreatic islets. D, The pancreatic cryosections from 12-month-old WT and Nlrp3/ mice fed
60% HFD were stained with antiinsulin (red) and anti-IL-1 antibodies. The extreme right panel shows representative image of pancreatic
cryosections of 12-month-old DIO mice stained with macrophage marker F4/80 (with membrane staining, in red) and IL-1 (cytoplasmic, in green).
The nuclei are counterstained blue with 4,6-diamidino-2-phenylindole. The confocal images are representative of at least four mice and were
repeated thrice.
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yloid deposition in the pancreas of T2D patients (3, 4).
Recent studies demonstrate that along with ceramides (13)
and fatty acids (25), IAPP also activates the NLRP3
inflammasome, and overexpression of human IAPP in
pancreatic islets causes IL-1 activation (18). Our data
demonstrate that the activation of IL-1 in pancreas is
dependent in part on the NLRP3 inflammasome-depen-
dent mechanism. Consistent with relationship between
IL-1 and development of fibrosis (3, 4), we found that the
elimination of NLRP3 inflammasome-dependent IL-1
production protects the development of islet fibrosis in
chronically obese mice. Furthermore, obesity-induced
pancreatic -cell death is regulated by the NLRP3 inflam-
masome. Consistent with reduced -cell death and higher
insulin levels in NLRP3-deficient mice in late-stage obe-
sity, data showing that ablation of NLRP3 increases pan-
creatic islet size provide new information that inhibition of
NLRP3 may protect from T2D. These data also suggest
that as obesity progresses into an insulin-dependent stage
when -cells undergo exhaustion, the absence of NLRP3
inflammasome-mediated IL1 processing maintains -cells,
which then successfully compensates for persistent above-
normal glucose levels by producing more insulin. Recent
evidence suggests that the widely used sulfonylurea class
of hypoglycemic drug glyburide also blocks NLRP3 in-
flammasome (28). Furthermore, glyburide affords sub-
stantial protection from gram-negative sepsis in diabetic
patients (29). Taken together, these findings suggest that
inhibition of NLRP3 inflammasome may offer new ther-
apeutic approaches against the development of T2D in
dietary obesity. Our data suggest that the NLRP3 inflam-
masome-dependent innate immune-sensing pathway is an
important regulator of pancreatic posttranslational pro-
cessing of IL-1 in DIO.
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